What's happening in the industry

Keytruda gets first-ever biomarker-specific approval read on...

Roche’s VENTANA PD-L1 (SP263) assay gains CE label expansion to inform treatment decisions in lung cancer patients being considered for Keytruda (pembrolizumab) immunotherapy read on...

Leica Biosystems applauds FDA Primary Diagnosis clearance as a step forward in clinical acceptance of digital pathology read on...

Cancer screening firm Guardant Health raises $360 million to sequence tumor DNA of 1 million patients read on...

Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals for Next-Generation Sequencing oncology companion diagnostic in cholangiocarcinoma read on...

BRAF proficiency testing reporting adequate but could improve, analysis finds read on...

Merck, Incyte immunotherapy combination effective in lung cancer study read on...

AstraZeneca shares surge after key drug shows promise in lung cancer trial read on...

Myriad Genetics and Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx® test to identify patients with germline BRCA mutations for Rubraca (rucaparib) treatment read on...

Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma read on...

FDA approves Brigatinib for lung cancer read on...

Abbvie drug fails to meet primary endpoints read on...

PMC Board chair to pioneer novel oncology treatment as CEO of Aravive Biologics read on...

The IASLC Atlas of PD-L1 Immunohistochemistry (IHC) Testing in Lung Cancer released read on...

UK Cancer Drug Fund didn’t deliver value ‘to patients or society’ read on...

Whistle-blower tells of health insurers bilking Medicare read on...

Patent Trial and Appeal Board finds Abbvie’s Humira patent unpatentable read on...

New Chinese paper-based test that reveals blood type in mere seconds with 99.9% accuracy could impact medical laboratories in the US read on...

What you might have missed

FDA has approved Philips' digital pathology solution as a primary diagnosis tool – it’s about time
156K cancer patients could miss out on life-saving drugs every year in US and Europe
Transforming the pharma business model to prevent lost treatment opportunities and optimize return on investment
Test availability at launch can be underestimated, under-budgeted and under-resourced: an example using real-time, real world analysis of PD-L1
Personalized Medicine (PM) Connective Announces Achievement of Several Milestones
Realizing the Value of Precision Medicine: Today